Many hematopoietic malignancies including MPN, act as classical “activated kinase diseases” driven by a mutant activated receptor tyrosine kinase (e.g. FLT3-ITD, mutant c-KIT) or the downstream kinase. Here, NTRK1 is linked to myeloproliferative neoplasm.